VIP and Parkinson disease: In contrast, VIP has been linked to most of the neuropeptide immunomodulatory actions and has been explored as a potential anti-inflammatory target in animal models of Parkinson’s disease, where a single intracerebroventricular injection of VIP was able to reduce microglial activation and prevented neurodegeneration (Delgado and Ganea 2003).